A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effectiveness of anlotinib hydrochloride in the neoadjuvant
therapy of locally advanced, or unresectable pheochromocytoma or paragangliom(PPGL).
Anrotinib is used preoperatively in order to change unresectable tumors to resectable and
reduce the high risk of surgery.